Kellerhals Carrard represented Moderna in relation to CC-N’s inspection
Kellerhals Carrard represented Moderna biotechnology company as it was heard as a third party in the inspection of the Control Committee of the National Council (CC-N) that was launched in May 2020 regarding the handling of the COVID-19 pandemic by the Federal Authorities.
The final report of the CC-N was published on November 18, 2021. It concludes that the Federal Authorities made appropriate strategic decisions in quickly negotiating a contract with Moderna, which enabled fast and comprehensive access of Switzerland to the Moderna vaccine.
The Kellerhals Carrard team was led by partners Claudia Götz Staehelin (pictured left))and Oliver M. Brupbacher (pictured right) and included partner Jean–Rodolphe Fiechter, associate Marlen Schultze and junior associate Nadja Fischer.
